Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Regenxbio Inc RGNX

Healthcare Biotechnology
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three... see more

Recent & Breaking News (NDAQ:RGNX)

REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II

PR Newswire 2 days ago

REGENXBIO Announces Leadership Transition

PR Newswire 8 days ago

REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

PR Newswire June 5, 2024

REGENXBIO to Participate in Upcoming Investor Conferences

PR Newswire May 10, 2024

REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights

PR Newswire May 8, 2024

REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights

PR Newswire May 1, 2024

REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

PR Newswire April 24, 2024

REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD

PR Newswire March 28, 2024

REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days

PR Newswire March 27, 2024

REGENXBIO to Participate in Upcoming Investor Conferences

PR Newswire March 11, 2024

REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants

PR Newswire March 6, 2024

REGENXBIO Announces Proposed Public Offering of Common Stock

PR Newswire March 6, 2024

REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL

PR Newswire March 5, 2024

REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial

PR Newswire February 29, 2024

REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

PR Newswire February 27, 2024

REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

PR Newswire February 21, 2024

REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint

PR Newswire February 7, 2024

REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial

PR Newswire February 7, 2024

REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024

PR Newswire January 31, 2024

REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery

PR Newswire January 16, 2024